Bavarian Nordic Signs Contract with U.S. Government for Additional Smallpox Vaccine Jynneos

Contract to Replenish Vaccine Inventory and Support Future Services

Highlights:

• Contract valued at approximately USD 277 million, including USD 17 million for additional services from 2025 through.
• Contract will help replenish inventory of bulk vaccine required for future manufacturing.
• Contract follows the commercial launch of Bavarian Nordic's smallpox/mpox vaccine Jynneos earlier this year.

COPENHAGEN, Denmark, July 25, 2023 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) today announced that it has signed a contract with the U.S. Government for the procurement of approximately 10 million doses of its smallpox/mpox vaccine, Jynneos.

The contract, valued at approximately USD 277 million, includes approximately USD 17 million for additional services from 2025 through. The contract will help replenish the U.S. Strategic National Stockpile of bulk vaccine required for future manufacturing of Jynneos.

The contract follows the commercial launch of Bavarian Nordic's smallpox/mpox vaccine Jynneos earlier this year. Jynneos is a non-replicating vaccine that has been shown to be safe and effective in preventing smallpox and mpox.

Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, said: "We are pleased to sign this contract with the U.S. Government, which will help replenish the U.S. Strategic National Stockpile of smallpox vaccine and support future services. This contract is a testament to the value of Jynneos and our commitment to supporting global health security."